MedTrace Logo

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

NCT02222610 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-03-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy

Conditions

  • Radiation Retinopathy

Interventions

DRUG

0.5 mg ranibizumab

PROCEDURE

Targeted Retinal Photocoagulation (TRP)

TRP to areas of retinal ischemia

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Greater Houston Retina Research

    lead OTHER

Principal Investigators

  • Amy C Schefler, MD · Retina Consultants Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-23
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02222610 on ClinicalTrials.gov